Article ID: aa246f0114ada174cf3e831eb5c9086f733d6ea008d14840653fc127c3da4ccf
Source ID: secondary:businessinsurance.com
Published At: -
Extraction Method: bs4_heuristic
Body Text
Moderna rises on settlement, clearing vaccine patent dispute overhang - Business Insurance Skip to content Register for free Search Search Log In Risk Management Cyber Risks Pricing Trends Mergers & Acquisitions Technology Sponsored Content WSIA RISKWORLD Workers Comp & Safety Workers Comp Cost Control Pain Management Workplace Safety International EMEA Asia-Pacific Latin America People Events BI Intelligence Top 100 Agents & Brokers Best Places to Work 2025 Lists Directories Insurance Pricing BI Stock Index Magazine Current Issue Past Issues Subscribe Women to Watch ALL INsurance Resources Risk Perspectives Sponsored Content Webinars White Papers Risk Management Cyber Risks Pricing Trends Mergers & Acquisitions Technology Sponsored Content WSIA RISKWORLD Workers Comp & Safety Workers Comp Cost Control Pain Management Workplace Safety International EMEA Asia-Pacific Latin America People Events BI Intelligence Top 100 Agents & Brokers Best Places to Work 2025 Lists Directories Insurance Pricing BI Stock Index Magazine Current Issue Past Issues Subscribe Women to Watch ALL INsurance Resources Risk Perspectives Sponsored Content Webinars White Papers Risk Management Cyber Risks Pricing Trends Mergers & Acquisitions Technology Sponsored Content WSIA RISKWORLD Workers Comp & Safety Workers Comp Cost Control Pain Management Workplace Safety International EMEA Asia-Pacific Latin America People Events BI Intelligence Top 100 Agents & Brokers Best Places to Work 2025 Lists Directories Insurance Pricing BI Stock Index Magazine Current Issue Past Issues Subscribe Women to Watch ALL INsurance Resources Risk Perspectives Sponsored Content Webinars White Papers Risk Management Cyber Risks Pricing Trends Mergers & Acquisitions Technology Sponsored Content WSIA RISKWORLD Workers Comp & Safety Workers Comp Cost Control Pain Management Workplace Safety International EMEA Asia-Pacific Latin America People Events BI Intelligence Top 100 Agents & Brokers Best Places to Work 2025 Lists Directories Insurance Pricing BI Stock Index Magazine Current Issue Past Issues Subscribe Women to Watch ALL INsurance Resources Risk Perspectives Sponsored Content Webinars White Papers Moderna rises on settlement, clearing vaccine patent dispute overhang Coronavirus , Risk Management Mar 4, 2026 (Reuters) — Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing it to focus on its pipeline. Analysts noted the settlement, which involves paying up to $2.25 billion to a Roivant Sciences’ Genevant subsidiary, and Arbutus Biopharma, would shift investor focus back to Moderna’s cancer vaccines under development. This resolves all U.S. and international legal actions accusing Moderna of unauthorized use of lipid nanoparticle technology owned by Genevant and Arbutus in its COVID vaccine. “The company has certainty it is well funded through multiple late-stage oncology readouts expected in 2026 that represent new long-term growth drivers,” said William Blair analyst Myles Minter. The company’s stock has also fallen nearly 90% since its 2021 highs as COVID vaccine demand collapsed in the years following the pandemic. Moderna will pay $950 million upfront in July 2026, with an additional $1.3 billion contingent on the outcome of a separate legal appeal, while not owing royalties for the technology in its future vaccines, which is seen as a significant win for the company. The payments are not as substantial as Wall Street had feared at over $3 billion, said Citi’s Geoffrey Meacham. Bernstein analyst Courtney Breen said, however, if the payment does become necessary, it could reduce the company’s cash reserves to as low as $3.2 billion by 2026. Moderna expects reserves to be between $4.5 billion to $5 billion this year. Breen added this “narrows the tightrope” for Moderna, as timing and scale of its other lawsuit against Pfizer and BioNTech is unknown, and its management has been known to be too optimistic in the past. In 2022, Moderna sued Pfizer and BioNTech for infringing patents related to mRNA technology. BioNTech countersued Moderna in February, arguing Moderna’s next-generation COVID-19 shot, MNEXSPIKE, infringes one of its patents. Related News Alliant hires former Gallagher transportation leader March 4, 2026 WCRI research shows uptick in comp costs as workers lose Medicaid March 4, 2026 War puts airlines in insurance bind March 4, 2026 Zurich raises $5B to fund Beazley deal March 4, 2026 QBE to take full control of India JV March 4, 2026 Ships linked to U.S., U.K., Israel pay triple war risk rates March 4, 2026 Reinsurers increasingly tap Bermuda for casualty sidecar capital March 4, 2026 Drone strikes damage Amazon data centers March 4, 2026 QBE names new international CUO March 4, 2026 Facebook-f X-twitter Linkedin-in Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing. Never miss important news: Become a Business Insurance Online subscriber today Subscribe Now Information About Us Contact Advertise Privacy Policy Terms & Conditions Copyright 2026. BUSINESS INSURANCE HOLDINGS Member, Beacon International Group, Ltd.
Metadata (JSON)
{
"score": 13.116666666666667
}